Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events

19 Citationer (Scopus)

Abstract

Background: Lp(a) (lipoprotein[a])-lowering therapy to reduce cardiovascular disease is under investigation in phase 3 clinical trials. High Lp(a) may be implicated in peripheral artery disease (PAD), abdominal aortic aneurysms (AAAs), and major adverse limb events (MALE).

Objectives: The authors investigated the association of high Lp(a) levels and corresponding LPA genotypes with risk of PAD, AAA, and MALE.

Methods: The authors included 108,146 individuals from the Copenhagen General Population Study. During follow-up, 2,450 developed PAD, and 1,251 AAAs. Risk of MALE was assessed in individuals with PAD at baseline and replicated in the Copenhagen City Heart Study.

Results: Higher Lp(a) was associated with a stepwise increase in risk of PAD and AAA (P for trend
Conclusions: High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies.
OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind82
Udgave nummer24
Sider (fra-til)2265-2276
Antal sider12
ISSN0735-1097
DOI
StatusUdgivet - 12 dec. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events'. Sammen danner de et unikt fingeraftryk.

Citationsformater